{"count":5,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/9fb65ecc-d100-4763-bfdc-17860017431d/","filing_uuid":"9fb65ecc-d100-4763-bfdc-17860017431d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9fb65ecc-d100-4763-bfdc-17860017431d/print/","filing_document_content_type":"text/html","income":null,"expenses":"50973.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-04-10T12:57:08-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d9004eff-36db-4dd3-aedd-f02b5f3a0827/","filing_uuid":"d9004eff-36db-4dd3-aedd-f02b5f3a0827","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/d9004eff-36db-4dd3-aedd-f02b5f3a0827/print/","filing_document_content_type":"text/html","income":null,"expenses":"490000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Peter Wallace","dt_posted":"2026-04-20T20:03:14-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1000 Mylan Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Canonsburg","registrant_state":"PA","registrant_zip":"15317","registrant":{"id":26353,"url":"https://lda.gov/api/v1/registrants/26353/","house_registrant_id":33792,"name":"VIATRIS INC.","description":null,"address_1":"1000 Mylan Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Canonsburg","state":"PA","state_display":"Pennsylvania","zip":"15317","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PETER WALLACE","contact_telephone":"+1 202-507-5356","dt_updated":"2026-07-30T15:07:39.090404-04:00"},"client":{"id":134178,"url":"https://lda.gov/api/v1/clients/134178/","client_id":12,"name":"VIATRIS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138091,"prefix":"mr","prefix_display":"MR.","first_name":"WILL","nickname":null,"middle_name":null,"last_name":"DENT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138091,"prefix":"mr","prefix_display":"MR.","first_name":"WILL","nickname":null,"middle_name":null,"last_name":"DENT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72530,"prefix":null,"prefix_display":null,"first_name":"ANNE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138091,"prefix":"mr","prefix_display":"MR.","first_name":"WILL","nickname":null,"middle_name":null,"last_name":"DENT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Policy related to corporate governance","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"S.2296 National Defense Authorization Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138091,"prefix":"mr","prefix_display":"MR.","first_name":"WILL","nickname":null,"middle_name":null,"last_name":"DENT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/","filing_uuid":"4ebc8da1-b3f2-4f07-89b4-e0518e9bb822","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/print/","filing_document_content_type":"text/html","income":null,"expenses":"47670.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-07-15T11:58:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cc054f31-02d3-4941-b574-2955abb00d0c/","filing_uuid":"cc054f31-02d3-4941-b574-2955abb00d0c","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/cc054f31-02d3-4941-b574-2955abb00d0c/print/","filing_document_content_type":"text/html","income":null,"expenses":"360000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Peter Wallace","dt_posted":"2026-07-20T20:26:57-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1000 Mylan Boulevard","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Canonsburg","registrant_state":"PA","registrant_zip":"15317","registrant":{"id":26353,"url":"https://lda.gov/api/v1/registrants/26353/","house_registrant_id":33792,"name":"VIATRIS INC.","description":null,"address_1":"1000 Mylan Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Canonsburg","state":"PA","state_display":"Pennsylvania","zip":"15317","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PETER WALLACE","contact_telephone":"+1 202-507-5356","dt_updated":"2026-07-30T15:07:39.090404-04:00"},"client":{"id":134178,"url":"https://lda.gov/api/v1/clients/134178/","client_id":12,"name":"VIATRIS INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"IP Issues related to generic medicines Patent Settlements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72530,"prefix":null,"prefix_display":null,"first_name":"ANNE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66369,"prefix":null,"prefix_display":null,"first_name":"KATHARINE","nickname":null,"middle_name":null,"last_name":"HAYES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FIN","general_issue_code_display":"Financial Institutions/Investments/Securities","description":"Policy related to corporate governance","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72530,"prefix":null,"prefix_display":null,"first_name":"ANNE","nickname":null,"middle_name":null,"last_name":"WILSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"S.2296 National Defense Authorization Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69928,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"WALLACE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/9c466920-2ff3-4c68-b3f8-d6299a6aa2c5/","filing_uuid":"9c466920-2ff3-4c68-b3f8-d6299a6aa2c5","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/9c466920-2ff3-4c68-b3f8-d6299a6aa2c5/print/","filing_document_content_type":"text/html","income":null,"expenses":"49416.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-10-07T14:25:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy. Providing comments to Senate Finance on ways to lower health care costs. Providing comments to Senate HELP on the 340B program. Providing comments to CMS on the Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}